Levetiracetam Injection
Product Images NDC 58657-860

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 58657-860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Method Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25-count (25 Vial Carton Label)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) single-dose vials by Method Pharmaceuticals, LLC. The label indicates it is for intravenous use only, sterile, and must be diluted prior to administration. It includes storage instructions and a description of the vial contents.*

FDA Label Image

Equation 3 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 00)

An illustration showing a formula to calculate creatinine clearance (CLcr) normalized to body surface area (1.73 m²). The formula divides the creatinine clearance by the patient's body surface area and multiplies by 1.73 m².*

FDA Label Image

Equation 2 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 01)

A formula table displaying the calculation of creatinine clearance (CLcr) based on age, weight, serum creatinine level, and adjusted by a factor of 0.85 for female patients. The equation includes variables for age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Equation 1 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 02)

A mathematical formula panel illustrating the calculation of total daily dose (mL/day) for a drug. The formula specifies Total daily dose (mL/day) equals Daily dose (mg/kg/day) times patient weight (kg), all divided by the drug concentration in mg/mL, shown as (500 mg/5 mL). This panel aids in dosage calculations for intravenous administration.*

FDA Label Image

Single-dose-vial (5ml Single Dose Vial)

Label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection by Method Pharmaceuticals, LLC. The label specifies a 5 mL single-dose vial, sterile, Rx only, with storage instructions and a barcode. It includes usage notes stating the solution must be diluted prior to administration.*

FDA Label Image

10-count (Carton Label)

Carton label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection from Method Pharmaceuticals, LLC. The package contains 10 single-dose vials of 5 mL each. The label includes storage instructions and a note that the product is for intravenous use only and must be diluted prior to administration.*

FDA Label Image

Structural Formula (Image 01)

Chemical structure of levetiracetam, the active ingredient in LEVETIRACETAM 500 mg/5mL Injection by Method Pharmaceuticals, LLC. The diagram depicts the molecular arrangement including a pyrrolidone ring and side chains.*

FDA Label Image

Figure 1 (Image 02)

A bar graph depicting the percentage of patients for placebo and two dosage levels of levetiracetam (1,000 mg/day and 3,000 mg/day). The y-axis represents the percentage of patients, showing approximately 7.4% for placebo, 37.1% for 1,000 mg/day, and 39.6% for 3,000 mg/day, with statistical significance noted versus placebo.*

FDA Label Image

Figure 2 (Image 03)

A bar graph showing the percentage of patients responding to different treatments: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. The vertical axis represents the percentage of patients from 0% to 45%. Response rates are 6.3% for placebo (N=111), 20.8% for Levetiracetam 1,000 mg/day (N=106), and 35.2% for Levetiracetam 2,000 mg/day (N=105). Statistically significant differences compared to placebo are indicated for both Levetiracetam doses.*

FDA Label Image

Figure 3 (Image 04)

A bar chart displaying the percentage of patients responding to treatments. It compares placebo with Levetiracetam 3,000 mg/day, showing 14.4% for placebo (N=104) and 39.4% for Levetiracetam (N=180). The Levetiracetam bar is marked as statistically significant versus placebo.*

FDA Label Image

Figure 4 (Image 05)

A vertical bar chart comparing the percentage of patients in two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The chart includes a note indicating the difference is statistically significant versus placebo.*

FDA Label Image

Figure 5 (Image 06)

A bar chart comparing the percentage of patients between a placebo group (19.6%) and a levetiracetam group (43.1%), with a note indicating statistical significance between levetiracetam and placebo.*

FDA Label Image

Figure 6 (Image 07)

A bar chart comparing the percentage of patients for Placebo (N=84) and Levetiracetam (N=79). The Placebo group shows 45.2% of patients, while the Levetiracetam group shows 72.2%, marked with an asterisk indicating statistical significance versus placebo. The vertical axis represents the percentage of patients from 0% to 100%.*

FDA Label Image

Single-dose-carton-labe (Single Dose Carton Label)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection single-dose vial. The label displays the brand name LEVETIRACETAM, includes usage instructions indicating intravenous use and dilution prior to administration, and shows Method Pharmaceuticals, LLC as the manufacturer. The package contains one 5 mL vial.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.